Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987007 | 0.80 | CRBN (0.57) | CRBN | |
| SCHEMBL2732740 | 0.78 | CRBN (0.55) | CRBN | |
| SCHEMBL27447930 | 0.78 | CRBN (0.55) | CRBN | |
| SCHEMBL20788754 | 0.76 | OTUD7B (0.33) | — | |
| SCHEMBL19586437 | 0.76 | CRBN (0.64) | CRBN | |
| SCHEMBL278215 | 0.72 | CRBN (0.50) | CRBN | |
| SCHEMBL24230501 | 0.72 | OTUD7B (0.39) | — | |
| SCHEMBL5435030 | 0.70 | CRBN (0.48) | CRBN | |
| SCHEMBL277887 | 0.70 | CRBN (0.48) | CRBN | |
| SCHEMBL278221 | 0.70 | CRBN (0.48) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3454862-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CRBN 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.